[HTML][HTML] Management of hepatotoxicity of chemotherapy and targeted agents
TW Mudd, AK Guddati - American journal of cancer research, 2021 - ncbi.nlm.nih.gov
Hepatotoxicity of chemotherapeutic agents such as methotrexate, oxaliplatin, and irinotecan
have been well documented and characterized allowing for careful management by …
have been well documented and characterized allowing for careful management by …
Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives
RR Shah, J Morganroth, DR Shah - Drug safety, 2013 - Springer
The introduction of small-molecule tyrosine kinase inhibitors (TKIs) in clinical oncology has
transformed the treatment of certain forms of cancers. As of 31 March 2013, 18 such agents …
transformed the treatment of certain forms of cancers. As of 31 March 2013, 18 such agents …
Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis
Y Zhao, B Cheng, Z Chen, J Li, H Liang, Y Chen… - Critical Reviews in …, 2021 - Elsevier
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are treatments
commonly used for lung cancer. The toxicity profile including toxicity incidence, severity, and …
commonly used for lung cancer. The toxicity profile including toxicity incidence, severity, and …
Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk/benefit
RR Shah, J Morganroth - Drug Safety, 2015 - Springer
We previously reviewed the cardiovascular safety of 16 tyrosine kinase inhibitors (TKIs),
approved for use in oncology as of 30 September 2012. Since then, the indications for some …
approved for use in oncology as of 30 September 2012. Since then, the indications for some …
Hepatotoxicity of small molecule protein kinase inhibitors for cancer
M Viganò, M La Milia, MV Grassini, N Pugliese… - Cancers, 2023 - mdpi.com
Simple Summary This review reports the risk and management of the hepatotoxicity of all the
approved protein kinase inhibitors (PKIs) for cancer. Hepatotoxicity is one of the major safety …
approved protein kinase inhibitors (PKIs) for cancer. Hepatotoxicity is one of the major safety …
Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review
Introduction: Existing clinical evidence indicates that many tyrosine kinase inhibitors (TKIs)
are associated with idiosyncratic hepatotoxicity. TKIs possess risk factors for developing …
are associated with idiosyncratic hepatotoxicity. TKIs possess risk factors for developing …
Drug-induced liver injury: a summary of recent advances
JG Stine, JH Lewis - Expert opinion on drug metabolism & …, 2011 - Taylor & Francis
Introduction: The knowledge base of drug-induced liver injury (DILI) continues to grow each
year as additional drugs are identified as hepatotoxins. There is still a need to improve our …
year as additional drugs are identified as hepatotoxins. There is still a need to improve our …
[HTML][HTML] Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a …
S Niho, Y Ohe, S Ishikura, S Atagi, A Yokoyama… - Annals of oncology, 2012 - Elsevier
Background We conducted a feasibility study of induction chemotherapy followed by
gefitinib and thoracic radiotherapy (TRT) for unresectable locally advanced adenocarcinoma …
gefitinib and thoracic radiotherapy (TRT) for unresectable locally advanced adenocarcinoma …
The dissociation of gefitinib trough concentration and clinical outcome in NSCLC patients with EGFR sensitive mutations
S Xin, Y Zhao, X Wang, Y Huang, J Zhang, Y Guo… - Scientific reports, 2015 - nature.com
Gefitinib is an essential drug for NSCLC patients harboring EGFR sensitive mutations. The
approved dose 250mg/day is based on limited clinical trials, this research aims to explore …
approved dose 250mg/day is based on limited clinical trials, this research aims to explore …
Hepatotoxicity of targeted therapy for cancer
Introduction: Understanding the mechanism of DILI with MTA, and how to avoid and manage
these toxicities is essential for minimising inferior cancer treatment outcomes. An organised …
these toxicities is essential for minimising inferior cancer treatment outcomes. An organised …